A Phase 4 interventional study of gabapentin 600 mg and gabapentin 1200 mg in Abuse Potential, sponsored by Viatris Specialty LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-24.
Sponsored by Viatris Specialty LLC (part of Viatris Inc.) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female participants with drug abuse experience with sedative drugs.
The study includes Screening, a Qualification Phase consisting of a Naloxone Challenge and Drug Discrimination crossover study, a Treatment Phase and Follow-up. Following successful completion of the Qualification Phase the participants will be enrolled in the Treatment phase. The Treatment Phase is a randomized, double-blind, double dummy, placebo- and active controlled, 5 treatment, 10-sequence, 5 period crossover, single-dose, Williams square design study in healthy male and/or female adult, non drug-dependent recreational users. On Day 1 of each of the Treatment Phase 5 periods, which will be separated by a washout of at least 14 days, participants will receive an oral dose of either NEURONTIN® 1800 mg, 1200 mg or 600 mg or 20 mg diazepam, or placebo. Study treatments will be administered under fasted conditions (overnight fast and no food until 4 hours after dosing). Water will be allowed without restriction until 1 hour prior to dosing and 1 hour after dosing.
Viatris Specialty LLC is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed to be clinically significant in the opinion of the investigator:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose
Drug: gabapentin 600 mg
single dose
Drug: diazepam 20 mg
single dose
Other: placebo
single dose
Drug: gabapentin 1200 mg
single dose
Drug: gabapentin 1800 mg
participants will receive an oral dose of gabapentin 600 mg
participants will receive an oral dose of gabapentin 1200 mg
participants will receive an oral dose of gabapentin 1800 mg
participants will receive an oral dose of 20 mg dose of diazepam
participants will receive an oral dose of placebo
Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).
Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
Time frame: up to 72 hours after treatments
Bipolar VAS for "Drug Liking" (Time for Maximum Effect, Emax [TEmax])
Time after dosing when the maximum effect for Drug Liking VAS is reached
Time frame: up to 72 hours after treatments
Bipolar VAS for "Drug Liking" (Area Under the Effect-time Profile From Time 0 to the Time of the Last Quantifiable Concentration [AUEClast])
Area under the effect-time profile from time 0 to the time of the last available data for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking". The minimum and maximum possible scores are approximately 0 and 7200 if a subject scores 0 mm (strong disliking) and 100 mm (strong liking) respectively at every timepoint up to 72 hours.
Time frame: Up to 72 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours)
Unipolar VAS for "High" (Maximum Effect, Emax)
Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 ="extremely"
Time frame: up to 72 hours after treatments
Unipolar VAS for "High" (Time for Maximum Effect, Emax [TEmax])
Time after dosing when the maximum effect for "High" VAS is reached
Time frame: up to 72 hours after treatments
Unipolar VAS for "High" (Area Under the Effect-time Profile From Time 0 to the Time of the Last Quantifiable Concentration [AUEClast])
Area under the effect-time profile from time 0 to the time of the last available data for the "High" visual analog scale which measures on a 100 mm visual analog scale the subject's response to the question "I am feeling high" where 0 ="not at all" and 100 ="extremely". The minimum and maximum possible scores are 0 and approximately 7200 if a subject scores 0 mm (not at all) and 100 mm (extremely) respectively at every timepoint up to 72 hours.
Time frame: Up to 72 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours)
Bipolar VAS for "Take Drug Again" at 24 Hour Post Dose
100 mm visual analog scale for the question "I would take this drug again" where 0 ="definitely not", 50 = "neutral", and 100 = "definitely so".
Time frame: At 24 hours after treatment
Bipolar VAS for "Take Drug Again" at 36 Hour Post Dose
100 mm visual analog scale for the question "I would take this drug again" where 0 ="definitely not", 50 = "neutral", and 100 = "definitely so".
Time frame: At 36 hours after treatment
Bipolar VAS for "Take Drug Again" at 48 Hour Post Dose
100 mm visual analog scale for the question "I would take this drug again" where 0 ="definitely not", 50 = "neutral", and 100 = "definitely so".
Time frame: At 48 hours after treatment
Bipolar VAS for "Take Drug Again" at 72 Hour Post Dose
100 mm visual analog scale for the question "I would take this drug again" where 0 ="definitely not", 50 = "neutral", and 100 = "definitely so".
Time frame: At 72 hours after treatment
Bipolar VAS for "Overall Drug Liking" at 24 Hour Post Dose
100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".
Time frame: At 24 hours after treatment
Bipolar VAS for "Overall Drug Liking" at 36 Hour Post Dose
100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".
Time frame: At 36 hours after treatment
Bipolar VAS for "Overall Drug Liking" at 48 Hour Post Dose
100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".
Time frame: At 48 hours after treatment
Bipolar VAS for "Overall Drug Liking" at 72 Hour Post Dose
100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".
Time frame: At 72 hours after treatment
Cmax of Gabapentin
Maximum plasma concentration (Cmax) of gabapentin
Time frame: Up to 72 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours)
Tmax of Gabapentin
Time when the maximum concentration of gabapentin is reached
Time frame: Up to 72 hours after treatments (concentrations were measured at the following timepoints after each treatment for thisoutcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 and 72 hours)
AUClast of Gabapentin
Area under the effect time profile from time 0 to the time of the last quantifiable concentration (AUClast) of gabapentin
Time frame: up to 72 hours after treatment (concentrations were measured at the following timepoints after each treatment for thisoutcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 and 72 hours)
Terminal Half-life of Gabapentin
Terminal half-life (t½) of gabapentin
Time frame: up to 72 hours after treatment (concentrations were measured at the following timepoints after each treatment for thisoutcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 and 72 hours)
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 6 | 5 | 5 | 5 | 6 | 5 | 5 | 5 |
| Completed | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 5 |
| Not completed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). | 51.98 ± 0.955 | 79.37 ± 2.533 | 61.95 ± 2.418 | 61.39 ± 2.209 | 60.95 ± 2.270 |
Time after dosing when the maximum effect for Drug Liking VAS is reached
| Hours | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking" (Time for Maximum Effect, Emax [TEmax]) | 0.2 (0.2 to 72) | 1.51 (0.2 to 8.0) | 2.0 (0.2 to 48.0) | 2.0 (0.2 to 12.0) | 2.5 (0.2 to 12.0) |
Area under the effect-time profile from time 0 to the time of the last available data for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking". The minimum and maximum possible scores are approximately 0 and 7200 if a subject scores 0 mm (strong disliking) and 100 mm (strong liking) respectively at every timepoint up to 72 hours.
| units on a scale * hour | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking" (Area Under the Effect-time Profile From Time 0 to the Time of the Last Quantifiable Concentration [AUEClast]) | 3441.77 ± 101.695 | 3778.02 ± 124.372 | 3588.67 ± 107.642 | 3601.72 ± 46.538 | 3652.27 ± 114.555 |
Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 ="extremely"
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Unipolar VAS for "High" (Maximum Effect, Emax) | 5.80 ± 2.272 | 61.56 ± 5.056 | 23.02 ± 4.351 | 26.93 ± 4.717 | 27.66 ± 4.753 |
Time after dosing when the maximum effect for "High" VAS is reached
| Hours | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Unipolar VAS for "High" (Time for Maximum Effect, Emax [TEmax]) | 0.20 (0.2 to 6.0) | 1.96 (0.2 to 6.0) | 1.50 (0.2 to 8.0) | 2.00 (0.2 to 8.0) | 2.50 (0.2 to 24.0) |
Area under the effect-time profile from time 0 to the time of the last available data for the "High" visual analog scale which measures on a 100 mm visual analog scale the subject's response to the question "I am feeling high" where 0 ="not at all" and 100 ="extremely". The minimum and maximum possible scores are 0 and approximately 7200 if a subject scores 0 mm (not at all) and 100 mm (extremely) respectively at every timepoint up to 72 hours.
| units on a scale * hour | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Unipolar VAS for "High" (Area Under the Effect-time Profile From Time 0 to the Time of the Last Quantifiable Concentration [AUEClast]) | 15.06 ± 5.993 | 250.38 ± 40.596 | 83.08 ± 23.583 | 112.74 ± 39.041 | 109.07 ± 24.600 |
100 mm visual analog scale for the question "I would take this drug again" where 0 ="definitely not", 50 = "neutral", and 100 = "definitely so".
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Take Drug Again" at 24 Hour Post Dose | 48.66 ± 1.955 | 63.10 ± 3.218 | 58.28 ± 2.453 | 55.63 ± 2.318 | 54.90 ± 2.773 |
100 mm visual analog scale for the question "I would take this drug again" where 0 ="definitely not", 50 = "neutral", and 100 = "definitely so".
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Take Drug Again" at 36 Hour Post Dose | 49.27 ± 1.392 | 64.95 ± 2.846 | 55.33 ± 2.546 | 55.73 ± 1.988 | 54.93 ± 2.403 |
100 mm visual analog scale for the question "I would take this drug again" where 0 ="definitely not", 50 = "neutral", and 100 = "definitely so".
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Take Drug Again" at 48 Hour Post Dose | 49.24 ± 1.390 | 62.24 ± 3.232 | 55.90 ± 1.954 | 52.80 ± 1.785 | 53.59 ± 2.150 |
100 mm visual analog scale for the question "I would take this drug again" where 0 ="definitely not", 50 = "neutral", and 100 = "definitely so".
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Take Drug Again" at 72 Hour Post Dose | 49.17 ± 1.402 | 63.88 ± 3.679 | 55.90 ± 1.921 | 53.76 ± 2.583 | 54.46 ± 2.184 |
100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Overall Drug Liking" at 24 Hour Post Dose | 48.20 ± 1.909 | 63.66 ± 3.578 | 57.10 ± 2.560 | 54.15 ± 2.618 | 53.90 ± 2.602 |
100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Overall Drug Liking" at 36 Hour Post Dose | 49.59 ± 1.584 | 61.83 ± 2.962 | 54.75 ± 2.952 | 55.63 ± 1.757 | 53.49 ± 2.109 |
100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Overall Drug Liking" at 48 Hour Post Dose | 49.68 ± 1.467 | 61.07 ± 2.992 | 54.83 ± 2.485 | 54.66 ± 2.156 | 53.37 ± 2.107 |
100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".
| Score on a scale | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| Bipolar VAS for "Overall Drug Liking" at 72 Hour Post Dose | 49.56 ± 1.503 | 61.46 ± 3.449 | 55.68 ± 2.117 | 55.10 ± 2.222 | 53.46 ± 2.606 |
Maximum plasma concentration (Cmax) of gabapentin
| nanograms/milliliter | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|
| Cmax of Gabapentin | 4223.47 ± 1048.963 | 6106.90 ± 1355.048 | 7373.15 ± 1874.185 |
Time when the maximum concentration of gabapentin is reached
| Hours | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|
| Tmax of Gabapentin | 2.78 (1.0 to 6.1) | 2.55 (1.0 to 6.1) | 2.55 (1.0 to 6.1) |
Area under the effect time profile from time 0 to the time of the last quantifiable concentration (AUClast) of gabapentin
| nanograms*hour/milliliter | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|
| AUClast of Gabapentin | 41848.88 ± 10659.677 | 66972.60 ± 15921.032 | 80483.05 ± 22369.826 |
Terminal half-life (t½) of gabapentin
| Hours | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|
| Terminal Half-life of Gabapentin | 7.69 ± 2.496 | 13.83 ± 12.988 | 14.43 ± 11.130 |
Collected over During the entire Treatment Phase of the study, which encompassed the time interval from admission of the subject to their first Treatment Period until 28 days after study drug dosing in their last (6th) Treatment Period, including the washout in between. The total duration of the Treatment Phase for each subject was dependent on visit scheduling and whether the subject completed treatment periods, and it lasted up to approximately 13 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/50 (0%) | 0/50 (0%) | 11/50 (22%) |
| Diazepam 20 mg | 0/50 (0%) | 0/50 (0%) | 30/50 (60%) |
| Gabapentin 600 mg | 0/52 (0%) | 0/52 (0%) | 20/52 (38.5%) |
| Gabapentin 1200 mg | 0/52 (0%) | 0/52 (0%) | 24/52 (46.2%) |
| Gabapentin 1800 mg | 0/51 (0%) | 0/51 (0%) | 23/51 (45.1%) |
| Event | Placebo | Diazepam 20 mg | Gabapentin 600 mg | Gabapentin 1200 mg | Gabapentin 1800 mg |
|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 2/50 | 15/50 | 7/52 | 8/52 | 10/51 |
| LethargyNervous system disorders | 2/50 | 6/50 | 4/52 | 2/52 | 2/51 |
| Euphoric moodPsychiatric disorders | 1/50 | 6/50 | 6/52 | 5/52 | 4/51 |
| FatigueGeneral disorders | 1/50 | 5/50 | 3/52 | 4/52 | 2/51 |
| DizzinessNervous system disorders | 0/50 | 2/50 | 1/52 | 5/52 | 5/51 |
| Feeling of relaxationGeneral disorders | 2/50 | 4/50 | 3/52 | 0/52 | 2/51 |
| HeadacheNervous system disorders | 0/50 | 1/50 | 0/52 | 4/52 | 3/51 |
| Depressed level of consciousnessNervous system disorders | 0/50 | 0/50 | 0/52 | 0/52 | 3/51 |
| SedationNervous system disorders | 1/50 | 0/50 | 0/52 | 2/52 | 0/51 |
| NauseaGastrointestinal disorders | 1/50 | 0/50 | 1/52 | 2/52 | 1/51 |
All participants who completed all 5 treatment periods of the Treatment Phase, excluding those subjects who had scores for the primary endpoint (maximum Drug Liking Visual Analog Scale score) that were within 5 points across all 5 treatments and/or had high placebo scores for the primary endpoint (maximum Drug Liking Visual Analog Scale score for placebo was \> 60 on a 100 point scale and the primary endpoint for placebo was 5 or more points greater than that for the positive control, diazepam)
| Age, Continuous(Years) | Modified Completer Population |
|---|---|
| Mean | 34.2 ± 9.15 |
| Sex: Female, Male(Participants) | Modified Completer Population |
|---|---|
| Female | 10 |
| Male | 31 |
| Ethnicity (NIH/OMB)(Participants) | Modified Completer Population |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 35 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Modified Completer Population |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 12 |
| White | 25 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Modified Completer Population |
|---|---|
| United States | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Nov 2022, 19 months.
Results were first posted in Dec 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin